Emyria Limited (ASX: EMD)

Market Cap	12.27M
Revenue (ttm)	2.20M
Net Income (ttm)	-11.46M
Shares Out	408.99M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,480
Open	0.0300
Previous Close	0.0310
Day's Range	0.0300 - 0.0300
52-Week Range	0.0265 - 0.0870
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Emyria

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is ...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In 2024, Emyria's revenue was 2.20 million, an increase of 38.32% compared to the previous year's 1.59 million. Losses were -11.46 million, 123.3% more than in 2023.